Tirdzniecība Catalent Inc - CTLT CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.27 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.030779% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.013666% | ||||||||
| Nakts laika nodeva | 22:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Catalent Inc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 56.52 |
| Atvērt* | 55.37 |
| Izmaiņas par 1 gadu* | -47.85% |
| Dienas Diapazons* | 54.98 - 57.2 |
| 52 ned Diapazons | 40.69-115.34 |
| Vidējais apjoms (10 dienas) | 2.47M |
| Vidējais apjoms (3 mēneši) | 60.37M |
| Tirgus Kapitalizācija | 10.09B |
| Cenas/Peļņas Attiecība | 23.98 |
| Izvietotās Akcijas | 179.96M |
| Ieņēmumi | 4.83B |
| EPS | 2.34 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 1.25 |
| Nākamās Peļņas Datums | Feb 7, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Feb 3, 2023 | 55.95 | 1.05 | 1.91% | 54.90 | 57.39 | 54.60 |
| Feb 2, 2023 | 56.52 | 1.82 | 3.33% | 54.70 | 57.83 | 54.70 |
| Feb 1, 2023 | 54.61 | 1.33 | 2.50% | 53.28 | 54.68 | 51.72 |
| Jan 31, 2023 | 53.42 | 0.70 | 1.33% | 52.72 | 53.45 | 52.12 |
| Jan 30, 2023 | 52.46 | 0.11 | 0.21% | 52.35 | 54.20 | 52.35 |
| Jan 27, 2023 | 53.50 | 2.05 | 3.98% | 51.45 | 53.99 | 51.45 |
| Jan 26, 2023 | 52.14 | 1.97 | 3.93% | 50.17 | 52.20 | 50.17 |
| Jan 25, 2023 | 50.04 | 1.17 | 2.39% | 48.87 | 50.07 | 48.03 |
| Jan 24, 2023 | 49.43 | -1.92 | -3.74% | 51.35 | 51.46 | 48.84 |
| Jan 23, 2023 | 52.46 | 3.37 | 6.86% | 49.09 | 52.54 | 48.65 |
| Jan 20, 2023 | 49.32 | 0.30 | 0.61% | 49.02 | 49.45 | 48.19 |
| Jan 19, 2023 | 49.17 | 1.78 | 3.76% | 47.39 | 49.69 | 46.48 |
| Jan 18, 2023 | 48.05 | 0.19 | 0.40% | 47.86 | 49.14 | 47.86 |
| Jan 17, 2023 | 47.83 | -0.58 | -1.20% | 48.41 | 48.70 | 47.18 |
| Jan 13, 2023 | 48.93 | 0.68 | 1.41% | 48.25 | 49.18 | 47.70 |
| Jan 12, 2023 | 49.24 | 0.15 | 0.31% | 49.09 | 49.42 | 48.31 |
| Jan 11, 2023 | 49.30 | 0.57 | 1.17% | 48.73 | 50.19 | 48.25 |
| Jan 10, 2023 | 47.95 | 0.40 | 0.84% | 47.55 | 48.88 | 47.55 |
| Jan 9, 2023 | 48.06 | 0.36 | 0.75% | 47.70 | 48.93 | 47.70 |
| Jan 6, 2023 | 47.55 | 1.31 | 2.83% | 46.24 | 47.64 | 44.28 |
Catalent Inc Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Kopējie ienākumi | 1848.1 | 2075.4 | 2463.4 | 2518 | 3094.3 | 3998 |
| Ienākumi | 1848.1 | 2075.4 | 2463.4 | 2518 | 3094.3 | 3998 |
| Cost of Revenue, Total | 1260.5 | 1420.8 | 1710.8 | 1712.9 | 2111 | 2646 |
| Bruto Peļņa | 587.6 | 654.6 | 752.6 | 805.1 | 983.3 | 1352 |
| Kopējie Darbības Izdevumi | 1630.3 | 1845.5 | 2204.1 | 2259.9 | 2716.2 | 3188 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 350.5 | 395.6 | 456.3 | 508.7 | 575.3 | 687 |
| Pētniecība un Attīstība | 7.6 | 7 | 6.3 | 3.3 | 2.6 | |
| Neparedzēti Izdevumi (Ienākumi) | 11.7 | 22.1 | 30.7 | 35 | 27.3 | -164 |
| Darbības Izdevumi | 217.8 | 229.9 | 259.3 | 258.1 | 378.1 | 810 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -75.9 | -94.3 | -106.8 | -110.4 | -123.1 | -115 |
| Citi, Neto | 3 | 0 | -0.5 | 12.6 | 5.4 | 20 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 144.9 | 135.6 | 152 | 160.3 | 260.4 | 715 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 111.2 | 109.8 | 126.2 | 137.4 | 220.7 | 585 |
| Mazākuma Interese | 0.3 | 0 | 0 | |||
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 111.5 | 109.8 | 126.2 | 137.4 | 220.7 | 585 |
| Ārkārtas Posteņi Kopā | 0 | 0 | -42.6 | |||
| Neto Ienākumi | 111.5 | 109.8 | 83.6 | 137.4 | 220.7 | 585 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 111.5 | 109.8 | 126.2 | 137.4 | 173 | 529 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 111.5 | 109.8 | 83.6 | 137.4 | 173 | 529 |
| Atšķaidītie Neto Ienākumi | 111.5 | 109.8 | 83.6 | 137.4 | 173 | 529 |
| Atšķaidītie Ienākumi par Akcijām | 125.87 | 126.738 | 133.201 | 145.954 | 152.322 | 170 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 0.88583 | 0.86636 | 0.94744 | 0.94139 | 1.13575 | 3.11176 |
| Dividends per Share - Common Stock Primary Issue | 0 | |||||
| Atšķaidītā Normalizētā Peļņa par Akciju | 0.95717 | 1.00755 | 1.1388 | 1.14693 | 1.28765 | 2.4139 |
| Total Adjustments to Net Income | -47.7 | -56 | ||||
| Other Operating Expenses, Total | 19 |
| Q3 2021 | Q4 2021 | Q1 2021 | Q2 2021 | Q3 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 1053.3 | 1188.2 | 1025 | 1217 | 1273 |
| Ienākumi | 1053.3 | 1188.2 | 1025 | 1217 | 1273 |
| Cost of Revenue, Total | 687.7 | 748.9 | 701 | 812 | 850 |
| Bruto Peļņa | 365.6 | 439.3 | 324 | 405 | 423 |
| Kopējie Darbības Izdevumi | 701.9 | 937.7 | 891 | 1056 | 1062 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 172.7 | 184.1 | 183 | 228 | 207 |
| Neparedzēti Izdevumi (Ienākumi) | -158.5 | 2.8 | 3 | 0 | 0 |
| Darbības Izdevumi | 351.4 | 250.5 | 134 | 161 | 211 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -33.8 | -30.8 | -35 | -47 | -37 |
| Citi, Neto | -0.5 | 1.8 | 4 | 1 | 2 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 317.1 | 221.5 | 103 | 115 | 176 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 231.8 | 182.4 | 93 | 97 | 141 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 231.8 | 182.4 | 93 | 97 | 141 |
| Neto Ienākumi | 231.8 | 182.4 | 93 | 97 | 141 |
| Total Adjustments to Net Income | -14.7 | -13.5 | -9 | -4 | 0 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 217.1 | 168.9 | 84 | 93 | 141 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 217.1 | 168.9 | 84 | 93 | 141 |
| Atšķaidītie Neto Ienākumi | 217.1 | 168.9 | 84 | 93 | 141 |
| Atšķaidītie Ienākumi par Akcijām | 172.5 | 171.5 | 172 | 177 | 181 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 1.25855 | 0.98484 | 0.48837 | 0.52542 | 0.77901 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Atšķaidītā Normalizētā Peļņa par Akciju | 0.58688 | 1.00741 | 0.52512 | 0.60644 | 0.80114 |
| Other Operating Expenses, Total | 1.9 | 4 | 16 | 5 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 790.2 | 1059.8 | 1240.3 | 1395.8 | 2293 | 2918 |
| Nauda un Īstermiņa Ieguldījumi | 131.6 | 306.9 | 410.2 | 345.4 | 953.2 | 967 |
| Nauda un Ekvivalenti | 131.6 | 288.3 | 410.2 | 345.4 | 953.2 | 896 |
| Debitoru Parādu Kopsumma, Neto | 414.8 | 488.8 | 555.8 | 716.4 | 899.5 | 1193 |
| Accounts Receivable - Trade, Net | 414.8 | 488.8 | 555.8 | 716.4 | 899.5 | 1193 |
| Total Inventory | 165.6 | 196.7 | 220.2 | 265.3 | 346.9 | 593 |
| Prepaid Expenses | 36.1 | 23.8 | 38.9 | 45.1 | 62.6 | 118 |
| Other Current Assets, Total | 42.1 | 43.6 | 15.2 | 23.6 | 30.8 | 47 |
| Total Assets | 3091.1 | 3454.3 | 4531.1 | 6184 | 7776.5 | 9112 |
| Property/Plant/Equipment, Total - Net | 905.8 | 995.9 | 1270.6 | 1536.7 | 2002.2 | 2608 |
| Property/Plant/Equipment, Total - Gross | 1550.7 | 1707.7 | 2097.9 | 2450.1 | 3046.8 | 3787 |
| Accumulated Depreciation, Total | -644.9 | -711.8 | -827.3 | -913.4 | -1044.6 | -1179 |
| Goodwill, Net | 996.5 | 1044.1 | 1397.2 | 2220.9 | 2470.6 | 2519 |
| Intangibles, Net | 294 | 273.1 | 544.9 | 930.8 | 888.7 | 817 |
| Other Long Term Assets, Total | 104.6 | 81.4 | 78.1 | 99.8 | 122 | 250 |
| Total Current Liabilities | 391.2 | 469 | 576.9 | 670.7 | 893.2 | 1196 |
| Accounts Payable | 143.7 | 163.2 | 192.1 | 255.8 | 321 | 385 |
| Accrued Expenses | 134.8 | 171.6 | 186.1 | 174.7 | 303.8 | 401 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 27.7 | 24.6 | 71.9 | 76.5 | 72.9 | 75 |
| Other Current Liabilities, Total | 85 | 109.6 | 126.8 | 163.7 | 195.5 | 335 |
| Total Liabilities | 2455.2 | 2730.8 | 3444.4 | 3895.8 | 4271.1 | 4838 |
| Total Long Term Debt | 1832.8 | 2055.1 | 2649.4 | 2882.8 | 2945.1 | 3166 |
| Long Term Debt | 1832.8 | 2055.1 | 2649.4 | 2882.8 | 2816.7 | 2988 |
| Deferred Income Tax | 41.4 | 31.7 | 32.5 | 74.4 | 94 | 164 |
| Minority Interest | 0 | |||||
| Other Liabilities, Total | 189.8 | 175 | 185.6 | 267.9 | 338.8 | 312 |
| Total Equity | 635.9 | 723.5 | 1086.7 | 2288.2 | 3505.4 | 4274 |
| Common Stock | 1.2 | 1.3 | 1.3 | 1.5 | 1.6 | 2 |
| Additional Paid-In Capital | 1976.5 | 1992 | 2283.3 | 2757.4 | 3818.7 | 4205 |
| Retained Earnings (Accumulated Deficit) | -1036.1 | -955.7 | -872.1 | -723.4 | -535.2 | 25 |
| Other Equity, Total | -305.7 | -324.6 | -324.7 | -304.8 | -385.2 | -316 |
| Total Liabilities & Shareholders’ Equity | 3091.1 | 3454.3 | 4531.1 | 6184 | 7776.5 | 9112 |
| Total Common Shares Outstanding | 124.712 | 125.05 | 133.424 | 145.7 | 162.8 | 170.5 |
| Īstermiņa Ieguldījumi | 18.6 | 0 | 71 | |||
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | |
| Unrealized Gain (Loss) | 10.5 | -1.1 | -49.1 | -1.1 | -1 | |
| Redeemable Preferred Stock | 606.6 | 606.6 | 359 | |||
| Total Preferred Shares Outstanding | 0.65 | 0.65 | 0.38478 | |||
| Capital Lease Obligations | 128.4 | 178 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 2774.5 | 2918 | 3931 | 2974 | 3025 |
| Nauda un Īstermiņa Ieguldījumi | 1062.8 | 967 | 2019 | 915 | 880 |
| Nauda un Ekvivalenti | 988.1 | 896 | 1969 | 849 | 786 |
| Īstermiņa Ieguldījumi | 74.7 | 71 | 50 | 66 | 94 |
| Debitoru Parādu Kopsumma, Neto | 1012.3 | 1193 | 1055 | 1179 | 1259 |
| Accounts Receivable - Trade, Net | 1012.3 | 1193 | 1055 | 1179 | 1259 |
| Total Inventory | 555.1 | 593 | 653 | 709 | 697 |
| Prepaid Expenses | 107.2 | 118 | 151 | 110 | 133 |
| Other Current Assets, Total | 37.1 | 47 | 53 | 61 | 56 |
| Total Assets | 8769.1 | 9112 | 10183 | 10203 | 10322 |
| Property/Plant/Equipment, Total - Net | 2358.8 | 2608 | 2581 | 2727 | 2820 |
| Property/Plant/Equipment, Total - Gross | 3480.4 | 3787 | 3796 | 3982 | 4128 |
| Accumulated Depreciation, Total | -1121.6 | -1179 | -1215 | -1255 | -1308 |
| Goodwill, Net | 2515 | 2519 | 2531 | 3026 | 3012 |
| Intangibles, Net | 834.8 | 817 | 793 | 1132 | 1097 |
| Other Long Term Assets, Total | 286 | 250 | 347 | 344 | 368 |
| Total Current Liabilities | 1139.2 | 1196 | 1096 | 1045 | 1046 |
| Accounts Payable | 365.7 | 385 | 363 | 363 | 401 |
| Accrued Expenses | 351 | 401 | 346 | 362 | 390 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 73.6 | 75 | 79 | 29 | 29 |
| Other Current Liabilities, Total | 348.9 | 335 | 308 | 291 | 226 |
| Total Liabilities | 4696.9 | 4838 | 5803 | 5722 | 5690 |
| Total Long Term Debt | 3149.6 | 3166 | 4225 | 4191 | 4157 |
| Long Term Debt | 3149.6 | 2988 | 4225 | 4191 | 4157 |
| Deferred Income Tax | 100.3 | 164 | 171 | 189 | 211 |
| Other Liabilities, Total | 307.8 | 312 | 311 | 297 | 276 |
| Total Equity | 4072.2 | 4274 | 4380 | 4481 | 4632 |
| Redeemable Preferred Stock | 359 | 359 | 359 | 0 | 0 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 1.7 | 2 | 2 | 2 | 2 |
| Additional Paid-In Capital | 4185.7 | 4205 | 4234 | 4615 | 4630 |
| Retained Earnings (Accumulated Deficit) | -150.3 | 25 | 114 | 209 | 350 |
| Unrealized Gain (Loss) | -1.1 | -1 | -1 | -2 | -3 |
| Other Equity, Total | -322.8 | -316 | -328 | -343 | -347 |
| Total Liabilities & Shareholders’ Equity | 8769.1 | 9112 | 10183 | 10203 | 10322 |
| Total Common Shares Outstanding | 170.133 | 170.5 | 171 | 179 | 179 |
| Total Preferred Shares Outstanding | 0.38478 | 0.38478 | 0 | 0 | 0 |
| Capital Lease Obligations | 178 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | 111.2 | 109.8 | 83.6 | 137.4 | 220.7 | 585 |
| Nauda no Darbības | 155.3 | 299.5 | 374.5 | 247.7 | 440.3 | 433 |
| Nauda no Darbības | 140.6 | 146.5 | 190.1 | 228.6 | 253.7 | 289 |
| Deferred Taxes | -15.3 | -1.3 | 35.4 | -15.1 | 2.4 | 64 |
| Bezskaidras Naudas Preces | 20.5 | 56.3 | 56.6 | 57.1 | 84.8 | -73 |
| Cash Taxes Paid | 40.6 | 39.8 | 23.9 | 42.2 | 43.4 | 47 |
| Samaksātie Procenti Naudā | 82.4 | 80.8 | 83.2 | 102.5 | 98.4 | 105 |
| Izmaiņas Apgrozāmajā Kapitālā | -101.7 | -11.8 | 8.8 | -160.3 | -121.3 | -432 |
| Nauda no Ieguldījumu Darbībām | -137.7 | -309 | -919.3 | -1510.4 | -827.5 | -649 |
| Kapitālie Izdevumi | -139.6 | -139.8 | -176.5 | -218.1 | -465.8 | -686 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 1.9 | -169.2 | -742.8 | -1292.3 | -361.7 | 37 |
| Nauda no Darbībām ar Finansēšanu | -30.8 | 161.3 | 669.1 | 1201.4 | 1001.7 | 142 |
| Naudas Plūsma Finansēšanas Posteņos | -14.5 | -11.8 | -29.3 | -39.3 | -56.9 | -55 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 0 | 0 | 277.8 | 1091.8 | 1046.5 | 120 |
| Parādu Izsniegšana (Atkāpšanās), Neto | -16.3 | 173.1 | 420.6 | 148.9 | 48.3 | 99 |
| Ārvalstu Valūtas Ietekme | -6.5 | 4.9 | -2.4 | -3.5 | -6.7 | 17 |
| Neto Izmaiņas Naudā | -19.7 | 156.7 | 121.9 | -64.8 | 607.8 | -57 |
| Total Cash Dividends Paid | -36.2 | -22 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 402.6 | 585 | 93 | 190 | 331 |
| Cash From Operating Activities | 298.7 | 433 | 163 | 232 | 370 |
| Cash From Operating Activities | 216 | 289 | 81 | 179 | 278 |
| Deferred Taxes | 17.8 | 64 | -8 | 1 | 13 |
| Non-Cash Items | -94.3 | -73 | 46 | 90 | 108 |
| Cash Taxes Paid | 24.8 | 47 | 15 | 27 | 40 |
| Cash Interest Paid | 97 | 105 | 40 | 50 | 93 |
| Changes in Working Capital | -243.4 | -432 | -49 | -228 | -360 |
| Cash From Investing Activities | -435.9 | -649 | -167 | -1299 | -1490 |
| Capital Expenditures | -497.1 | -686 | -154 | -277 | -425 |
| Other Investing Cash Flow Items, Total | 61.2 | 37 | -13 | -1022 | -1065 |
| Cash From Financing Activities | 159.3 | 142 | 1082 | 1033 | 1030 |
| Financing Cash Flow Items | -40.3 | -55 | -15 | -18 | -15 |
| Total Cash Dividends Paid | -17.7 | -22 | -4 | -4 | -4 |
| Issuance (Retirement) of Stock, Net | 103.9 | 120 | 8 | 19 | 21 |
| Issuance (Retirement) of Debt, Net | 113.4 | 99 | 1093 | 1036 | 1028 |
| Foreign Exchange Effects | 12.8 | 17 | -5 | -13 | -20 |
| Net Change in Cash | 34.9 | -57 | 1073 | -47 | -110 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 10.639 | 19146397 | 178443 | 2022-09-30 | LOW |
| T. Rowe Price Investment Management, Inc. | Investment Advisor | 10.2356 | 18420356 | 4856175 | 2022-09-30 | HIGH |
| Capital World Investors | Investment Advisor | 6.3398 | 11409408 | 1109522 | 2022-09-30 | LOW |
| Veritas Asset Management LLP | Investment Advisor/Hedge Fund | 6.2067 | 11169815 | 4212040 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.0359 | 9062767 | 211705 | 2022-09-30 | LOW |
| Capital Research Global Investors | Investment Advisor | 4.3601 | 7813960 | 7813960 | 2022-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.9601 | 7126800 | 67054 | 2022-09-30 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 3.7863 | 6813891 | -210135 | 2022-09-30 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 3.2611 | 5868803 | 636031 | 2022-09-30 | LOW |
| Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 3.1373 | 5645971 | -15644 | 2022-09-30 | LOW |
| Leonard Green & Partners, L.P. | Private Equity | 2.4106 | 4338292 | 7830 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9485 | 3506644 | 79559 | 2022-09-30 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 1.8853 | 3392876 | 401891 | 2022-09-30 | LOW |
| American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.7178 | 3091425 | -477166 | 2022-09-30 | LOW |
| JP Morgan Asset Management | Investment Advisor | 1.6948 | 3050107 | -385335 | 2022-09-30 | LOW |
| EARNEST Partners, LLC | Investment Advisor/Hedge Fund | 1.2444 | 2239391 | 46349 | 2022-09-30 | LOW |
| Carmignac Gestion | Investment Advisor/Hedge Fund | 0.9825 | 1768186 | 1128205 | 2022-09-30 | MED |
| T. Rowe Price Associates, Inc. | Investment Advisor | 0.9452 | 1701051 | -461899 | 2022-09-30 | LOW |
| Viking Global Investors LP | Investment Advisor/Hedge Fund | 0.9301 | 1673755 | -287494 | 2022-09-30 | MED |
| Bessemer Trust Company, N.A. (US) | Investment Advisor | 0.9176 | 1651393 | -17467 | 2022-09-30 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group +485000+
Tirgotāji
65000+
Ikmēneša aktīvie klienti
$48000000+
Ikmēneša ieguldījumu apjoms
$28000000+
Izmēģināt tagad Izņemts katru mēnesi
Treidinga kalkulators
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Tirdzniecības komisija
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Finanšu svira
20:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Catalent Company profile
Par Catalent Inc
Catalent, Inc. piedāvā piegādes tehnoloģijas, kā arī izstrādes un ražošanas risinājumus zālēm, proteīnu, šūnu un gēnu terapijas bioloģiskajiem preparātiem un patērētāju veselības produktiem. Uzņēmuma segmentos ietilpst Softgel un perorālās tehnoloģijas, Bioloģiskās zāles, Perorālās un speciālās piegādes un Klīniskās piegādes pakalpojumi. Mīksto kapsulu un perorālo tehnoloģiju segments nodarbojas ar mīksto kapsulu formulēšanas, izstrādes un ražošanas pakalpojumu sniegšanu, kā arī ar perorālo cieto devu formu liela mēroga ražošanu. Bioloģisko zāļu segments sniedz bioloģisko šūnu līniju, šūnu terapijas un vīrusu vektoru gēnu terapijas izstrādes un ražošanas pakalpojumus. Perorālās un speciālās piegādes segments nodrošina preparātu izstrādi un ražošanu, izmantojot dažādas tehnoloģijas, kā arī integrētus pakārtotus klīniskās izstrādes un komerciālās piegādes risinājumus. Klīniskās piegādes pakalpojumu segments nodarbojas ar zāļu un bioloģisko zāļu ražošanu, iepakošanu, izplatīšanu un krājumu pārvaldību klīniskajos pētījumos.
| Industry: | Pharmaceuticals (NEC) |
14 Schoolhouse Rd
SOMERSET
NEW JERSEY 08873-1213
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 485 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com